Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest and land in Latvia

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of 100% of the shares in the two Latvian companies SIA "Latvijas Mežu Aģentūra" and SIA "Vadakstes Meži" (the “Companies") from Skogsfond Baltikum AB (publ). The Companies own a total of 8,080 hectares of forest and land in Latvia.
December 16, 2024

Vinge advises Abliva on the public offer from Pharming

Pharming Technologies B.V., a wholly owned subsidiary of Pharming Group N.V., has announced a public offer to the shareholders of Abliva AB (publ). The total value of the offer is approximately SEK 725 million.
December 16, 2024

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024